The Effectiveness And Safety Of Sox Regimen Versus Gemox Regimen In The Treatment Of Patients With Advanced Hepatocellular Carcinoma

OBJECTIVETo compare the effectiveness and safety of oxaliplatin plus S-1 (SOX regimen) versus oxaliplatin plus gemcitabine (GEMOX regimen) in the treatment of patients with advanced hepatocellular carcinoma.METHODS88 advanced hepatocellular carcinoma patients who received SOX regimen (n=46) or GEMOX regimen(n=42) in the Affiliated Cancer Hospital of Guangxi Medical University were retrospectively analyzed. SOX regimen is oxaliplatin 130 mg/m2,iv,dl and S-140mg/m2, bid,po, dl-14. GEMOX regimen is oxaliplatin 130 mg/m2,iv,dl and gemcitabine 1000 mg/m2, iv,dl,d8. The two regimens both repeat every 21 days. According to the RECIST 1.1 standard to evaluate the objectively curative effect. According to the NCICTC 4.0 standard to evaluate the adverse reactions. To compare the response rate(RR), disease control rate(DCR), the medium progression free survival(mPFS), the medium overall survival(mOS), AFP response rate, ECOG score improvement rate and safety.RESULT88 patients can be evaluated for effectiveness and adverse reaction. The median follow-up time is 12.4 months(95%CI,11.8-15.1 months). The RR in SOX and GEMOX groups were 13.04%(6/46) and 11.90%(5/42), P=0.87. DCR were 52.17% (24/46) and 69.04%(29/42), P=0.11. The mPFS were 4.36 month (95%CI,3.38-5.33 month) and 4.55 month(95%CI,3.29-5.82 month)(i^0.95); The mOS were 9.60 month (95%CI,8.09-11.10 month) and 8.42 month (95%CI,6.89-9.96 month) (P=0.16). There were no obvious difference between SOX regimen and GEMOX regimen for RR, DCR, mPFS and mOS. AFP reaction rate were 10.87%(5/46) and 14.29%(6/42), P=0.31. The ECOG score improvement rate were 10.87%(5/46)å'Œ 16.67%(7/42), P=0.16. The major toxicities were leucopenia in two regimens,60.87% (28/46) vs.50.00% (21/42), P=0.25. Compared with GEMOX regimen, SOX regimen had higher incidences of gastrointestinal reaction and lower incidences of thrombocytopenia(P< 0.05). Grade â… -â…¡ neurotoxicity can be seen in both groups,30.43% (14/46) vs. 21.43%(9/42),P=0.31.CONCLUSIONThe effectiveness between SOX regimen and GEMOX regimen in the treatment of patients with advanced hepatocellular carcinoma have no obvious difference, They are safe and can be a choose for patients with advanced hepatocellular carcinoma.